Xenetic Biosciences, Inc. (XBIO) stock intrinsic value fair value estimate & owner earnings analysis

Xenetic Biosciences is a very small biotechnology company. Its only revenue is royalty income (about $3.0 million in 2025, up from $2.5 million in 2024) from a single partner, Takeda, which sublicenses Xenetic's PolyXen drug-delivery technology for blood and bleeding disorder products. The royalties are a single-digit percentage of Takeda's net sales of covered products. Xenetic's own patents on this older technology are expiring over the next few years and the company has said it is not renewing them. Its research effort is now centered on a DNase enzyme program that is still pre-clinical, with no product, no approval and no revenue. The business has not produced positive owner earnings in any year we can measure. After removing working-capital swings and stock compensation, owner earnings were about negative $7.0 million in 2019 and have narrowed each year since, to about negative $2.4 million in 2025 (roughly negative $1.43 per share). The narrowing came from lower spending and less stock compensation, not from a growing earnings base. In 2025 the royalty revenue of $3.0 million was more than absorbed by research spending of $3.1 million plus administrative costs. All three of our cases come out at $0 per share. Base case: royalties continue for the remaining life of the PolyXen patents and spending on the DNase program continues at roughly the current level, so the business keeps consuming cash rather than producing it. Bear case: the royalties end as the patents run out while the DNase program still needs funding, and additional shares would likely be sold to pay for it. Bull case: the DNase program is not credited because it has no data, partner or approval we can point to; the most favorable evidenced outcome is that royalties cover most costs for as long as the patents last, which still leaves nothing durable after they expire. Because our approach values only what the business earns after its own costs, and does not add the balance-sheet cash, the shares are assigned no value from operations. The company reported about $7.9 million of cash at the end of 2025 with about $1.0 million of current liabilities and no debt, so the shares are not without asset backing; that cash is being spent down at roughly $2 to $3 million a year, and it is not part of our valuation. Two items deserve a reader's attention. First, the company disclosed in its 2025 annual report that it has started a formal strategic review, including a possible sale or a reverse merger with another company, and has held preliminary discussions with third parties. We give it no value because no terms exist, and a reverse merger would probably leave current holders with a small minority of the combined company. Second, the company said its 2025 annual stockholder meeting was adjourned twice for lack of a quorum and had not yet been held when the report was filed; it lists Nasdaq continued-listing compliance as a risk. We found no exchange deficiency notice in the annual report. What would make this wrong: a partner agreement or acquisition for the DNase program on terms that produce cash to shareholders, or a transaction that brings in a profitable business. Neither is in the filings today. Management stated that current resources are adequate for at least the next twelve months, supported by a $4.0 million share offering in October 2025. Our data covers annual reports through fiscal 2025 and the June 2026 quarterly filing was not read in detail; per-share figures for 2019 to 2021 are restated for the 2022 reverse split. On owner earnings alone, the margin-of-safety price is $0 unless the business begins producing positive owner earnings.